The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. (Q35873720)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

Sarah Thompson

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Nathan Herrmann

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

1 September 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Safety

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

425-440

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

Extrapyramidal side effects in a patient treated with risperidone plus donepezil

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Neuroleptic malignant syndrome induced by donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Aricept-induced nightmares in Alzheimer's disease: 2 case reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Urinary incontinence: an unrecognised adverse effect with donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

A toxicokinetic model to assess the risk of azinphosmethyl exposure in humans through measures of urinary elimination of alkylphosphates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Discontinuation syndrome following donepezil cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.5.425

21 January 2018

Identifiers

DOI

10.1517/14740338.3.5.425

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15335298%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference